Lavaca Capital’s GSK GSK Stock Holding History

Lavaca Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.5K	Hold	154	–	–	﹤0.01%	260
2025 Q4	$7.55K	Hold	154	–	–	﹤0.01%	265
2025 Q3	$6.65K	Hold	154	–	–	﹤0.01%	253
2025 Q2	$5.91K	Hold	154	–	–	﹤0.01%	251
2025 Q1	$5.97K	Hold	154	–	–	﹤0.01%	231
2024 Q4	$5.21K	Buy	+154	New	+$5.54K	﹤0.01%	286
2019 Q2	–	Sell	-766	Closed	-$40K	–	194
2019 Q1	$40K	Hold	766	–	–	0.03%	167
2018 Q4	$37K	Buy	+766	New	+$37.7K	0.04%	142

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Lavaca Capital's GSK Position: Q1 2026 in Review

Lavaca Capital held its GSK (GSK) position steady in Q1 2026 at 154 shares worth $8.5K. The position accounts for ﹤0.01% of the portfolio, ranked #260.

Lavaca Capital first reported a position in GSK in Q4 2018 and has held it in 8 quarters since. The position peaked at $40K in Q1 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Lavaca Capital held 154 shares of GSK worth $8.5K as of Q1 2026.
Lavaca Capital left its GSK share count unchanged in Q1 2026.
GSK made up ﹤0.01% of Lavaca Capital's portfolio in Q1 2026, its #260 holding.
Lavaca Capital first reported a position in GSK in Q4 2018 and has held it in 8 quarters since.
Lavaca Capital's GSK position peaked at $40K in Q1 2019.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Lavaca Capital's 13F filing for Q1 2026, filed 13 May 2026.